| ［1］ |
Gonzaga MI, Grant L, Curtin C, et al. The epidemiology and survivorship of clear cell sarcoma: a National Cancer Database （NCDB） review［J］. J Cancer Res Clin Oncol, 2018,144（9）:1711⁃1716. doi: 10.1007/s00432⁃018⁃2693⁃6.
|
| ［2］ |
Kodiatte TA, George SV, Chacko RT, et al. Malignant melanocytic neoplasm of pancreas with liver metastasis: is it malignant melanoma or clear cell sarcoma?［J］. Indian J Pathol Microbiol, 2017,60（1）:102⁃104. doi: 10.4103/0377⁃4929.200054.
|
| ［3］ |
Cornillie J, van Cann T, Wozniak A, et al. Biology and management of clear cell sarcoma: state of the art and future perspectives［J］. Expert Rev Anticancer Ther, 2016,16（8）:839⁃845. doi: 10.1080/14737140.2016.1197122.
|
| ［4］ |
Liu H, Nazmun N, Hassan S, et al. BRAF mutation and its inhibitors in sarcoma treatment［J］. Cancer Med, 2020,9（14）:4881⁃4896. doi: 10.1002/cam4.3103.
|
| ［5］ |
杨馨蕊, 柳剑英, 苏静. 黑素瘤BRAF V600E突变的临床检测方法进展［J］. 临床皮肤科杂志, 2020,49（4）:253⁃256. doi: 10. 16761/j.cnki.1000⁃4963.2020.04.020.
|
| ［6］ |
Cipriani NA, Letovanec I, Hornicek FJ, et al. BRAF mutation in ′sarcomas′: a possible method to detect de⁃differentiated melanomas［J］. Histopathology, 2014,64（5）:639⁃646. doi: 10. 1111/his.12305.
|
| ［7］ |
Hocar O, Le Cesne A, Berissi S, et al. Clear cell sarcoma （malignant melanoma） of soft parts: a clinicopathologic study of 52 cases［J］. Dermatol Res Pract, 2012,2012:984096. doi: 10.1155/2012/984096.
|
| ［8］ |
Protsenko SA, Semionova AI, Komarov YI, et al. BRAF⁃mutated clear cell sarcoma is sensitive to vemurafenib treatment［J］. Invest New Drugs, 2015,33（5）:1136⁃1143. doi: 10.1007/s10637⁃015⁃0280⁃0.
|
